775 — CK Life Sciences Intl (Holdings) Balance Sheet
0.000.00%
- HK$8.55bn
- HK$14.25bn
- HK$5.52bn
- 26
- 19
- 48
- 17
Annual balance sheet for CK Life Sciences Intl (Holdings), fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 972 | 902 | 704 | 676 | 571 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 845 | 899 | 993 | 967 | 1,097 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 3,292 | 3,169 | 3,125 | 2,992 | 2,965 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,816 | 2,765 | 2,603 | 2,748 | 2,570 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 11,978 | 11,731 | 11,267 | 11,247 | 10,789 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 916 | 2,075 | 4,062 | 2,101 | 2,313 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7,256 | 7,227 | 7,109 | 7,058 | 7,277 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 4,721 | 4,504 | 4,158 | 4,189 | 3,512 |
| Total Liabilities & Shareholders' Equity | 11,978 | 11,731 | 11,267 | 11,247 | 10,789 |
| Total Common Shares Outstanding |